Invesco Pharmaceuticals ETF (NYSEARCA:PJP) Sets New 52-Week High – Here’s What Happened

Shares of Invesco Pharmaceuticals ETF (NYSEARCA:PJP) reached a new 52-week high during mid-day trading on Thursday. The company traded as high as $132.41 and last traded at $132.3850, with a volume of 2,566 shares trading hands. The stock had previously closed at $131.59.

Invesco Pharmaceuticals ETF Stock Performance

The firm has a market capitalization of $586.02 million, a PE ratio of 28.57 and a beta of 0.43. The firm has a fifty day moving average of $125.78 and a 200 day moving average of $114.83.

Institutional Trading of Invesco Pharmaceuticals ETF

Several large investors have recently bought and sold shares of the company. Bank of America Corp DE raised its stake in shares of Invesco Pharmaceuticals ETF by 234.0% during the first quarter. Bank of America Corp DE now owns 74,458 shares of the company’s stock valued at $7,726,000 after purchasing an additional 52,165 shares during the period. Royal Bank of Canada lifted its position in shares of Invesco Pharmaceuticals ETF by 479.8% during the first quarter. Royal Bank of Canada now owns 62,377 shares of the company’s stock worth $6,472,000 after purchasing an additional 51,619 shares in the last quarter. Trek Financial LLC purchased a new position in shares of Invesco Pharmaceuticals ETF in the third quarter valued at $5,720,000. Cetera Investment Advisers boosted its stake in shares of Invesco Pharmaceuticals ETF by 250.7% in the first quarter. Cetera Investment Advisers now owns 20,462 shares of the company’s stock valued at $2,123,000 after purchasing an additional 14,628 shares during the period. Finally, Outlook Wealth Advisors LLC purchased a new position in shares of Invesco Pharmaceuticals ETF in the third quarter valued at $1,392,000.

Invesco Pharmaceuticals ETF Company Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types.